Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.
about
HIV-1 neutralizing antibodies: understanding nature's pathwaysMucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal ChallengeHigh-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samplesA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinInfluence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primatesBreadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigsEnv-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virusNeutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay.A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness.Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaquesImmunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates.Structure-based vaccine design in HIV: blind men and the elephant?Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.Directed evolution of a yeast-displayed HIV-1 SOSIP gp140 spike protein toward improved expression and affinity for conformational antibodies.Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation.Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding siteBLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses.Neutralizing antibodies to HIV-1 induced by immunization.Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates.Direct Probing of Germinal Center Responses Reveals Immunological Features and Bottlenecks for Neutralizing Antibody Responses to HIV Env Trimer.Progress toward active or passive HIV-1 vaccination.Improvement of antibody responses by HIV envelope DNA and protein co-immunization.Modulation of HIV-1 immunity by adjuvants.Evolution of B cell analysis and Env trimer redesign.Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?
P2860
Q27000480-BFFE998C-9C06-4D8C-9F42-BF901BFFEC85Q27318151-B338004B-B83A-475C-9B08-668C46611680Q28389941-15681923-C6E2-48E2-80E7-8696B2227455Q28743092-BB58B4FB-985F-4471-A512-E19B50E985ACQ33614605-C0A936EE-670B-412A-A225-303F02E1688EQ33725679-8CC6ABB0-C2B3-4650-986D-23DAC3A11810Q33769283-F275F484-B910-45B5-BD20-3A1AE2C239C2Q33807535-0F988D2F-2B12-4D4F-9A2E-6196C5A52BC8Q34047445-FAE13F70-9B8C-424B-B928-E06ACA2C730EQ34096475-6A074036-6B94-4270-8FD9-CEBC6A0E0B88Q34096530-3FCA7879-8156-4E7D-AE9F-73F8F830B54DQ34120088-D66DFB90-CA95-4A64-88C2-936975F9E78AQ34133551-AE5C4DE8-A312-4D34-BDCD-26B0FA12A92EQ34204047-85566DEB-8B31-45B9-8092-D8159BAE4239Q34594513-9B8DC7BD-9D52-454E-9335-36C68CEC0C74Q34663118-C40C3089-C331-4D21-8BB5-BC0DEB32CAFAQ34880294-7117371E-3A36-4233-A213-AC32C858BBFDQ34987048-82BDF94E-909A-4483-B457-235F1C59FF9DQ35077438-1DA276BC-AE54-4A8F-A139-D38C098077DAQ35077716-50C853B7-19A4-4572-A50E-DF590D80C84BQ35092308-B1E4D0B7-EEB0-48D6-B7F3-4EE91D297598Q35169535-34CAA85F-0061-4A28-BB84-460ED901AE86Q35691113-633F63A2-AB2A-4B13-9295-24E2288F239EQ35774051-2A1129BA-C6D3-4CBE-BDD7-228C94E8C26AQ36016522-87F39330-9576-4104-AA22-FD20BB4B00B5Q36603515-BA747028-BB58-4AC2-8C44-31CE76D78A72Q36702114-3048A7FC-4574-4F96-98A4-BE233CEDCA83Q36878885-F270724B-871A-4191-A3A6-2181AF172C28Q37336704-4E8C7A0C-1512-4681-B6A7-5365B8A8134AQ37482035-6F837692-BE03-4555-A1FD-B705E9FFC5ADQ37549777-3DB03A31-B0C0-4860-89D0-501116BF59C5Q37588371-9200BB72-2DD8-446A-8AB4-A8000CEC8804Q37698564-F46F9612-CA4E-460D-ABF0-DC4167358416Q38992740-26250267-A3EF-488C-8FE8-80D16DD5B9EFQ40047250-A8442914-6B7F-4D9E-B2B5-DB29A4267671Q40198048-95310785-F4AE-4A43-A581-71D4B8976A55Q40463159-71C21004-24CF-401A-A4B5-C45388A4B3CCQ55436995-86D68FE3-2C4A-444D-987B-612E4D40E79C
P2860
Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Human immunodeficiency virus t ...... or or stabilized core protein.
@en
Human immunodeficiency virus t ...... or or stabilized core protein.
@nl
type
label
Human immunodeficiency virus t ...... or or stabilized core protein.
@en
Human immunodeficiency virus t ...... or or stabilized core protein.
@nl
prefLabel
Human immunodeficiency virus t ...... or or stabilized core protein.
@en
Human immunodeficiency virus t ...... or or stabilized core protein.
@nl
P2093
P2860
P50
P356
P1433
P1476
Human immunodeficiency virus t ...... tor or stabilized core protein
@en
P2093
Gerald Voss
Gunilla B Karlsson Hedestam
Iyadh Douagi
John R Mascola
Mattias N E Forsell
Peter D Kwong
Richard T Wyatt
Rigmor Thorstensson
Sijy O'Dell
P2860
P304
P356
10.1128/JVI.01102-08
P407
P577
2008-11-12T00:00:00Z